ZYME Quote, Financials, Valuation and Earnings

Oragenics has a net margin of -83.5% compared to Zymeworks's net margin of --. Zymeworks's return on equity of -30.32% beat Oragenics's return on equity of --.

Zymeworks has a consensus price target of $21.56, signalling upside risk potential of 67.23%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 1983.54%. Given that Oragenics has higher upside potential than Zymeworks, analysts believe Oragenics is more attractive than Zymeworks.

Zymeworks has a beta of 1.193, which suggesting that the stock is 19.333% more volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

Zymeworks has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Zymeworks quarterly revenues are $27.1M, which are larger than Oragenics quarterly revenues of --. Zymeworks's net income of -$22.6M is lower than Oragenics's net income of -$2.2M. Notably, Zymeworks's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks is 10.44x versus 0.46x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Rocket Pharmaceuticals has a net margin of -83.5% compared to Zymeworks's net margin of --. Zymeworks's return on equity of -30.32% beat Rocket Pharmaceuticals's return on equity of --.

Zymeworks has a consensus price target of $21.56, signalling upside risk potential of 67.23%. On the other hand Rocket Pharmaceuticals has an analysts' consensus of $9.03 which suggests that it could grow by 213.66%. Given that Rocket Pharmaceuticals has higher upside potential than Zymeworks, analysts believe Rocket Pharmaceuticals is more attractive than Zymeworks.

Zymeworks has a beta of 1.193, which suggesting that the stock is 19.333% more volatile than S&P 500. In comparison Rocket Pharmaceuticals has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.232%.

Zymeworks has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rocket Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks pays -- of its earnings as a dividend. Rocket Pharmaceuticals pays out -- of its earnings as a dividend.

Zymeworks quarterly revenues are $27.1M, which are larger than Rocket Pharmaceuticals quarterly revenues of --. Zymeworks's net income of -$22.6M is higher than Rocket Pharmaceuticals's net income of -$61.3M. Notably, Zymeworks's price-to-earnings ratio is -- while Rocket Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks is 10.44x versus -- for Rocket Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Semler Scientific has a net margin of -83.5% compared to Zymeworks's net margin of -732.34%. Zymeworks's return on equity of -30.32% beat Semler Scientific's return on equity of -23.56%.

Zymeworks has a consensus price target of $21.56, signalling upside risk potential of 67.23%. On the other hand Semler Scientific has an analysts' consensus of $71.00 which suggests that it could grow by 79.57%. Given that Semler Scientific has higher upside potential than Zymeworks, analysts believe Semler Scientific is more attractive than Zymeworks.

Zymeworks has a beta of 1.193, which suggesting that the stock is 19.333% more volatile than S&P 500. In comparison Semler Scientific has a beta of 1.392, suggesting its more volatile than the S&P 500 by 39.164%.

Zymeworks has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Semler Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks pays -- of its earnings as a dividend. Semler Scientific pays out -- of its earnings as a dividend.

Zymeworks quarterly revenues are $27.1M, which are larger than Semler Scientific quarterly revenues of $8.8M. Zymeworks's net income of -$22.6M is higher than Semler Scientific's net income of -$64.7M. Notably, Zymeworks's price-to-earnings ratio is -- while Semler Scientific's PE ratio is 8.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks is 10.44x versus 6.77x for Semler Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -83.5% compared to Zymeworks's net margin of --. Zymeworks's return on equity of -30.32% beat Theriva Biologics's return on equity of --.

Zymeworks has a consensus price target of $21.56, signalling upside risk potential of 67.23%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1455.56%. Given that Theriva Biologics has higher upside potential than Zymeworks, analysts believe Theriva Biologics is more attractive than Zymeworks.

Zymeworks has a beta of 1.193, which suggesting that the stock is 19.333% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Zymeworks has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Zymeworks quarterly revenues are $27.1M, which are larger than Theriva Biologics quarterly revenues of --. Zymeworks's net income of -$22.6M is lower than Theriva Biologics's net income of -$4.3M. Notably, Zymeworks's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks is 10.44x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.